All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study

Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Lawitz EJ, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, et al. Hepatology. 2015;61(4):1127-1135.

Publication Type:

Journal Article

Authors:

David R. Nelson; Cooper, J.N.; Lalezari, J.P.; et, al

Source:

Hepatology, Volume 61, Issue 4, p.1127-1135 (2015)

Keywords:

abnormalities, Florida, Genotype, HCV, hepatitis, Hepatitis C, hepatitis C virus, Infection, Laboratories, medication, NS5B inhibitor, Patients, Ribavirin, sofosbuvir, SVR, treatment, treatment-naive, Universities

Cited On:

External Third-party Web Link:

http://www.ncbi.nlm.nih.gov/pubmed/25614962

Export Citation:
RIS Format
Top